Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : FDA Grants Priority Review to J&J's Bedaquiline Tuberculosis Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 04:02pm CEST
   By Nathalie Tadena 
 

The Food and Drug Administration has granted accelerated approval for Johnson & Johnson's (JNJ) drug to treat a drug-resistant form of tuberculosis.

The drug, bedaquiline, has faced concerns about an imbalance of deaths seen in clinical studies. J&J's Janssen Research & Development had asked the FDA for accelerated approval of bedaquiline, which is a type of temporary approval based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group--but the prescribing information for the treatment will include boxed warnings regarding increased risk of death.

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether bedaquiline played a role in deaths seen in clinical studies. While the FDA has said the safety data currently available for bedaquiline suggest the product appears safe, there is a potential for the highest dose of the product to cause a small change in the heart's rhythm. The FDA had said there wasn't enough data to rule out potential drug side effects on the liver and the heart. There were more deaths seen among patients being treated with bedaquiline although most of the deaths were attributed to the underlying disease.

The consumer group Public Citizen has strongly opposed the accelerated approval of bedaquiline because clinical trials showed the drug could be highly dangerous.

Only about 100 cases of drug-resistant TB are seen each year in the U.S. but the problem is more severe in typically poor countries outside the U.S.

Tuberculosis is a bacterial infection that mostly involves the lungs. It is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Bedaquiline is designed to work in a new way to treat TB and would be used with other drugs.

However, there is evidence that some forms of TB can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the worldwide control of tuberculosis."

Tuberculosis can be fatal if it's not properly treated.

Write to Nathalie Tadena at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04/21JOHNSON & JOHNSON : J&J, BMS Team Up on Cardiovascular Therapies
AQ
04/20GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2018
AQ
04/20JOHNSON & JOHNSON : Reports 2018 First-Quarter Results
AQ
04/20JOHNSON & JOHNSON : Janssen Announces Worldwide Development and Commercializatio..
AQ
04/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Newly Published Phase 2 Study Found..
AQ
04/20JOHNSON & JOHNSON : Small biotech companies dominate the pipeline for Microbiome..
AQ
04/20JOHNSON & JOHNSON : Kentucky sues opioid manufacturers
AQ
04/20JOHNSON & JOHNSON : BioCentury - BenevolentAI raises $115M
AQ
04/19JOHNSON & JOHNSON : - Newly Published Phase 2 study Found Esketamine Demonstrate..
AQ
04/19JOHNSON & JOHNSON : Studies offer hope of HIV vaccine
AQ
More news
News from SeekingAlpha
04/22Johnson & Johnson Sells Off After Earnings 
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/21THE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Rising Inflationary Expectations Cap Equities 
04/20IBM, Exxon, J&J among expected dividend hikes next week 
Financials ($)
Sales 2018 81 466 M
EBIT 2018 25 020 M
Net income 2018 16 960 M
Debt 2018 10 763 M
Yield 2018 2,85%
P/E ratio 2018 18,46
P/E ratio 2019 17,17
EV / Sales 2018 4,30x
EV / Sales 2019 4,01x
Capitalization 340 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571
AMGEN-0.56%114 648